Back in May, Novartis scrambled to contain the fallout about its relationship with President Trump’s personal attorney, Michael Cohen, who was paid $1.2 million in consulting fees to provide access and insights into the new administration.
In carefully choreographed moments, the former chief executive, Joe Jimenez, took responsibility for the “mistake,” since he agreed to the one-year deal in early 2017. And his successor, Vas Narasimhan, who began running the company this past February, had already declined to renew the contract and vowed to uphold “ethical standards.”
About the Author Reprints
